Arbutus Biopharma (ABUS) revenue breakdown
By product, Collaborations and licenses is the largest at 89% of fiscal 2025 revenue, growing 19% a year over 6 years.
Revenue by product
Fiscal years, as Arbutus Biopharma reports them in its 10-K filings; fiscal 2025 total $14M.
| Products | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|
| Collaborations and licenses | $4M | $4M | $5M | $31M | $14M | $4M | $13M | 89% |
| Non-cash royalty revenue | $2M | $3M | $6M | $8M | $4M | $2M | $1M | 11% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ABUS.
Open ABUS in InvestinglyQuestions
Where does Arbutus Biopharma make its money?
In fiscal 2025, by product: Collaborations and licenses $13M, Non-cash royalty revenue $1M.
From Arbutus Biopharma's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.